Sarcoma  >>  AZD1390  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD1390 / AstraZeneca
SADDRIN-1, NCT05116254 / 2021-000042-17: Sarcomas and DDR-Inhibition; a Combined Modality Study

Recruiting
1
30
Europe
AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy
The Netherlands Cancer Institute, Leiden University Medical Center, University Medical Center Nijmegen
Soft Tissue Sarcoma Adult
03/26
07/28

Download Options